In a groundbreaking advancement for neurodegenerative disease diagnostics, Roche and Eli Lilly have received US Food and Drug Administration (FDA) approval for their blood-based test to detect Alzheimer’s disease, marking a major leap toward earlier, simpler, and more accessible diagnosis of the condition. The newly approved